


The Ramanbhai Foundation 8th International Symposium on Current Trends in Healthcare

"Advances in New Drug Discovery & Development"

Feb 2-4, 2017, Ahmedabad, India



Scientists and R & D professionals from across the globe will be at arms reach when they gather in Ahmedabad, from Feb 2-4, 2017, for the RBF 8th International Symposium. Niftily designed with eclectic thought-provoking sessions that will kindle and invigorate the scientific acumen with new age drug discovery and development techniques, the conference will live up to its tradition by providing scientists with an unparalleled knowledge-sharing platform to learn, stay ahead of dynamic trends and interact with a repertoire of R & D scientists and key opinion leaders.



The Ramanbhai Foundation
8th International Symposium



February 2-4, 2017
Ahmedabad, India

Important Dates :

Last date for Abstract Submission - January 15, 2017

Last date for Early Registration - January 15, 2017

Venue :

Gujarat University Convention and Exhibition Centre,
132 Ring Road, Near Helmet Circle, Opp Mayflower Hospital, Ahmedabad, Gujarat 380009

Event Sponsors

Zydus
dedicated to life

Zydus
Hospitals
A Complete Hospital

Academic Partners

INDIANA UNIVERSITY



Register online at www.rbfsymposium.net/registration.asp



February 2, 2017 (Thursday)

10:00 hrs **Welcome & Introductions**

Session I

Chairpersons:

- Richard DiMarchi Ph.D.; Standiford H. Cox Distinguished Professor of Chemistry, Indiana University

10:30 hrs



"The Problem of Reproducibility in Biomedical Research"

Jeff Flier, M.D.

Dean of the Faculty of Medicine,
Harvard Medical School, Harvard University

11:00 hrs



"Drug Development at Melanocortin Receptors for Obesity and Other Metabolic Disorders"

Roger Cone, Ph.D.

Chair of the Department of Molecular
Physiology and Biophysics, Vanderbilt University School of Medicine

11:30 hrs



"Discovery of New Protein Drug Targets by Comprehensively Screening the Extracellular Proteome"

Lewis T. "Rusty" Williams, M.D., Ph.D.

Founder, President and CEO, Five Prime Therapeutics, Inc.

12:00 hrs



"Mouse Models for Pharmacogenomic Discovery".

Karen Reue, Ph.D.

Professor, Human Genetics, Department of Human
Genetics, University of California, Los Angeles

12:30 hrs

Lunch

Session II : Gastrointestinal and Liver Diseases

Chairpersons:

- Terry Flier, MD; Associate Director and Advisor of Francis Weld Peabody Society, Harvard University

14:00 hrs



Jay Horton, MD

Distinguished Chair in Human Nutrition,
The University of Texas Southwestern, Medical Center

14:30 hrs



"Specificity Matters –Musings on (somewhat unconventional) development of a targeted immunomodulatory biologic"

Asit Parikh, MD, Ph.D

Head of GI Therapeutic Area Unit,
Takeda Pharmaceuticals

15:00 hrs



Mukul Jain, Ph. D.

Senior V P, Pharmacology & Toxicology
Zydus Research Center

15:30 hrs

Tea-Break

16:00 hrs



"Non-alcoholic steatohepatitis modulation by novel PPAR agonists"

Bart Staels, Ph.D.

Director UMR INSERM 1011,
Professor at the Faculty of Pharmacy, Université Lille 2, France

16:30 hrs



"State of the art diagnosis and management of NASH"

Naga Chalasani, M. D., FACC

Professor of Medicine,
Indiana University School of Medicine

17:00 hrs



"Translating scientific discovery into a cure for NASH"

Arun Sanyal, MD

Professor of Medicine, Physiology and Molecular Pathology
Virginia Commonwealth University

17:30 hrs

Wrap-up



February 3, 2017 (Friday)

Session III : Cancer Therapeutics

09:15 hrs **Introduction**

Chairpersons:

- Kapil Dhingra, MD; Retired Vice President, Roche, Director, KAPital Consulting LLC

09:30 hrs



"Enabling personalized medicine in oncology: Current status and perspectives on the future"

Kapil Dhingra, MD

Retired Vice President, Roche,
Director, KAPital Consulting LLC

10:00 hrs



Neal Rosen, MD, Ph.D.

Enid A. Haupt Chair in Medical Oncology,
Director, Center for Mechanism-Based Cancer Therapies,
Memorial Sloan-Kettering Cancer Center

10:30 hrs **Tea-Break**

11:00 hrs



"Discovery and Development of Novel Therapies in Advanced Breast Cancer"

Samit Hirawat, M.D

Senior Vice President, Global Program Head, Novartis Pharmaceuticals

11:30 hrs



Martin Pule, M.D.

Founder & Chief Scientific Officer
Autolus Limited

12:00 hrs **Lunch & Poster Session**

Session IV : Anti-infectives & Public Health

Chairpersons:

- Alok Dhawan, Ph.D., Director, CSIR-Indian Institute of Toxicology Research
- Reinhard Glueck, Ph.D; Chief Scientific Officer Zydus - VTC

14:00 hrs



"Public-Private Partnerships to Accelerate Innovation in Product Development"

Rajeev Venkayya, MD

President of Global Vaccine Business Unit,
Takeda Pharmaceuticals

14:30 hrs



"Developing next-generation malaria medicines to address drug resistance and increase the operational feasibility of malaria elimination efforts"

Jörg Möhrle, Ph.D.

Vice President, Head of Translational Medicine, Research & Development, Medicines
for Malaria Venture

15:00 hrs **Tea-Break**

15:30 hrs



"The Discovery and Development of New Antivirals"

Manoj Desai, Ph.D.

Vice President, Medicinal Chemistry
Gilead Sciences

16:00 hrs



"Opportunities and Challenges in the Vaccine Industry"

Rahul Singhvi, Sc.D.

Chief Operating Officer,
Takeda Vaccines

16:30 hrs

Panel Discussion

"Is there more integration between cancer, viral disease and the microbiome?"

17:30 hrs

Wrap-up



February 4, 2017 (Saturday)

Session V : Cardio-metabolic Diseases

09:00 hrs Introduction

Chairpersons:

- Jeff Flier, M.D.; Dean of the Faculty of Medicine, Harvard Medical School, Harvard University
- Naga Chalasani, M. D.; FACC, Professor of Medicine, Indiana University School of Medicine

09:10 hrs



Philip J. Larsen, MD, PhD

Senior Vice President, Global Head of Diabetes
Research and Translational Science, Sanofi-Aventis

09:40 hrs



"FGF21: physiology and therapeutic potential"

Terry Flier, MD

Professor of Medicine, Harvard Medical School
Division of Endocrinology, Beth Israel Deaconess Medical Center.

10:10 hrs



"Evolving mechanisms and continued challenges of the FGF-21 pathway as a therapeutic target"

Saswata Talukdar, Ph.D.

Director and Leader of CardioMetabolic Disease, Early Discovery group, Merck

10:40 hrs Tea-Break

11:10 hrs



"Atherogenicity of Triglyceride-rich lipoproteins (TRL) and Novel Therapies Aimed at Reducing Associated Cardiometabolic Risk"

Michael Miller, MD

Director, Center for Preventive Cardiology University of Maryland Medical Center

11:40 hrs



"Metabolism and metabolic aging"

Charles F. Burant, MD, Ph.D.

Professor of Metabolism, The Burant Lab, University of Michigan Medical School

12:10 hrs



"Hepatocyte PPAR α is protective against NAFLD in neonate and adult mice"

Walter Wahli, Ph.D

Professor of Metabolic Disease, Lee Kong
Chian School of Medicine, Nanyang Technological University

12:40 hrs Lunch & Poster Session

Session VI : Chemical Biotechnology

Chairpersons:

- Lewis T. "Rusty" Williams, M.D., Ph.D., Founder, President and CEO, Five Prime Therapeutics, Inc.

14:00 hrs



"Plants as bio-factories for producing peptide-based pharmaceuticals"

David Craik, Ph.D.

Group Leader, Chemistry and Structural
Biology Division, The University of Queensland

14:30 hrs



Phil Dawson, Ph.D.

Associate Dean of Graduate Studies,
Department of Chemistry California Campus, The Scripps Research Institute

15:00 hrs



"High productive cell-lines, ADC process development and challenges"

Palani Palaniappan, Ph.D.

Vice President & Head, Biologics & New Modalities Development,
Takeda Pharmaceuticals

15:30 hrs



"Chemical Biotechnology Applied to Metabolic Diseases"

Richard DiMarchi, Ph.D.

Standiford H. Cox Distinguished Professor of Chemistry,
Linda & Jack Gill Chair in Biomolecular Sciences, Indiana University

16:00 hrs

Best Poster Awards

- Oral Poster Presentation 1 (10 min)
- Oral Poster Presentation 2 (10 min)
- Oral Poster Presentation 3 (10 min)

16:30 hrs

Closing Comments